XML 75 R57.htm IDEA: XBRL DOCUMENT
v3.23.1

License Agreement - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions |  |  |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | ---
Mar. 23, 2020 | Apr. 25, 2017 | Jul. 07, 2014 | Mar. 31, 2020 | Apr. 30, 2019 | Jan. 31, 2018 | Apr. 30, 2016 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2019
License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |
Annual minimum royalty obligations |  |  |  |  |  |  |  | $ 0.2 |  |
License termination period |  |  |  |  |  |  |  | 60 days |  |
Common stock, shares issued |  |  |  |  |  |  |  | 66,228,046 | 65,392,758 |
Bristol Myers Squibb | Collaborative Arrangement |  |  |  |  |  |  |  |  |  |
License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront payment received |  | $ 200.0 | $ 50.0 |  |  |  |  | $ 297.0 |  |
Milestone payment received |  |  |  | $ 10.0 |  | $ 12.0 |  |  |  |
Astellas Pharma Inc. | Collaboration and License Agreement |  |  |  |  |  |  |  |  |  |
License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront payment received | $ 80.0 |  |  |  |  |  |  |  |  |
AbbVie Ireland Unlimited Company | Discovery Agreement |  |  |  |  |  |  |  |  |  |
License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  |  | $ 10.0 |  |  |
AbbVie Ireland Unlimited Company | CD71 Agreement |  |  |  |  |  |  |  |  |  |
License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  |  | $ 20.0 | 100.0 |  |
Immuno Gen Inc | Collaborative Arrangement |  |  |  |  |  |  |  |  |  |
License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  |  |  |  |  | $ 7.5
UCSB |  |  |  |  |  |  |  |  |  |
License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |
Common stock, shares issued |  |  |  |  | 150,000 |  |  |  |  |
Fair value of common stock price per share |  |  |  |  | $ 10.68 |  |  |  |  |
Payment of upfront fees |  |  |  |  | $ 1.0 |  |  |  |  |
Annual license maintenance fees |  |  |  |  | $ 0.8 |  |  |  |  |
License payment term |  |  |  |  | 2031 |  |  |  |  |
Percentage of remaining maintenance fees outstanding |  |  |  |  | 50.00% |  |  |  |  |
Sublicense fees |  |  |  |  |  |  |  | 1.0 | $ 1.0 |
Amgen | Collaboration and License Agreement |  |  |  |  |  |  |  |  |  |
License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |
Sublicense fees |  |  |  |  |  |  |  | $ 0.1 |  |

X
- Definition Annual license maintenance fees + References No definition available. + Details
Name: | ctmx_AnnualLicenseMaintenanceFees
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License payment term. + References No definition available. + Details
Name: | ctmx_LicensePaymentTerm
Namespace Prefix: | ctmx_
Data Type: | xbrli:gYearItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period of time to terminate license after notice date. + References No definition available. + Details
Name: | ctmx_LicenseTerminationPeriod
Namespace Prefix: | ctmx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone payments received from revenue recognized during period. + References No definition available. + Details
Name: | ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Payment of upfront fees. + References No definition available. + Details
Name: | ctmx_PaymentOfUpfrontFees
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of remaining maintenance fees outstanding. + References No definition available. + Details
Name: | ctmx_PercentageOfRemainingMaintenanceFeesOutstanding
Namespace Prefix: | ctmx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Royalty obligations future minimum payments due. + References No definition available. + Details
Name: | ctmx_RoyaltyObligationsFutureMinimumPaymentsDue
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Sublicense fees. + References No definition available. + Details
Name: | ctmx_SublicenseFees
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_CommonStockSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Cash received from collaborators during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromCollaborators
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | srt_CounterpartyNameAxis=ctmx_BristolMyersSquibbCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ctmx_AstellasPharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ctmx_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ctmx_DiscoveryAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ctmx_CD71AgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ctmx_ImmunoGenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ctmx_UniversityOfCaliforniaSantaBarbaraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ctmx_AmgenAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |